Ads
related to: parp inhibitors- Ovarian Cancer Overview
Access Information On An Ovarian
Cancer Treatment Option.
- Patient Information
Access Patient Info Regarding An
Ovarian Cancer Treatment Option.
- Ovarian Cancer Treatment
Explore An Ovarian Cancer Treatment
Option & Speak With Your Patients.
- Dosing And Administration
Explore Dosing Options For An
Ovarian Cancer Treatment.
- Ovarian Cancer Info
Learn More About Ovarian Cancer
& What It Means For Your Patients.
- View Supporting Resources
View Important Eligibility Info For
An Ovarian Cancer Treatment.
- Ovarian Cancer Overview
Search results
FDA Expands Pfizer's (PFE) Talzenna Label in Prostate Cancer
Zacks via Yahoo Finance· 11 months agoFollowing FDA's label-expansion approval, Pfizer's (PFE) Talzenna is the first PARP inhibitor...
AstraZeneca (AZN) Gets EU Nod to Expanded Use of 2 Cancer Drugs
Zacks via Yahoo Finance· 1 year agoAstraZeneca PLC AZN, along with partner Merck MRK, announced that the European Commission (EC) has...
Pfizer Releases Interim Update On PARP Inhibitor Combo Therapy For Prostate Cancer, Secures FDA...
Benzinga via Yahoo Finance· 1 year agoPfizer Inc (NYSE: PFE) announced results from the Phase 3 TALAPRO-2 study of Talzenna (talazoparib)...
Imunon, Inc. (NASDAQ:IMNN) Q3 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 6 months agoImunon, Inc. (NASDAQ:IMNN) Q3 2023 Earnings Call Transcript November 17, 2023 Operator: Good...
FDA Expands AstraZeneca (AZN) Lynparza Label in Prostate Cancer
Zacks via Yahoo Finance· 12 months agoFollowing FDA's label-expansion approval, AstraZeneca's (AZN)/Merck's (MRK) Lynparza is the first...
BeiGene (BGNE) to Report Q4 Earnings: What's in the Cards?
Zacks via Yahoo Finance· 3 months agoBeiGene BGNE is expected to report its fourth-quarter 2023 results soon. BeiGene currently markets...
FDA Delays Decision on AstraZeneca (AZN), Merck's Lynparza sNDA
Zacks via Yahoo Finance· 1 year agoThe FDA extends the review period of AstraZeneca (AZN)/Merck's filing seeking label expansion for...
Ideaya Nominates Potential First-In-Class Pol Theta Helicase Inhibitor In Collaboration With GSK
Benzinga via Yahoo Finance· 2 years agoIdeaya Biosciences Inc (NASDAQ: IDYA) has selected a potential first-in-class Pol Theta Helicase...
AstraZeneca-Merck's Lynparza Treatment Shows Long-Term Survival In Ovarian Cancer
Benzinga via Yahoo Finance· 2 years agoAstraZeneca plc (NASDAQ: AZN) and Merck & Co Inc (NYSE: MRK) announced long-term follow-up results...
GSK's oncology business suffers fresh blow with Zejula setback
Reuters via Yahoo News· 2 years ago(Reuters) -Britain's GSK said on Friday it would limit the use of its ovarian cancer drug Zejula in...
Ads
related to: parp inhibitors